In 1160 adults aged 75+ taking statins for primary prevention, stopping statins was non-inferior to continuing for 3-year all-cause mortality (7·2% vs 7·9%; difference -0·68%, 95% CI -3·95 to 2·60; margin 5%). Adverse events were similar (74·0% vs 73·1%).
RCTn = 1,180
Bonnet et al. Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial